Biophytis
About Biophytis
Biophytis Is A Biotechnology Company Created In 2006. It Develops First-In-Class Drugs To Treat Degenerative Illnesses Associated With Aging For Which There Is Currently No Treatment. Its Two Most Advanced Programmes Relate To Sarcopenia (Loss Of Muscle Functionality) And Age-Related Macular Degeneration (ARMD).YEAR FOUNDED:
2006
LEADERSHIP:
CEO: Stanislas Veillet PhD
CSO: Rene Lafont
Chief Medical Officer: Susanna Del Signore
130 articles about Biophytis
-
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
5/25/2023
Biophytis SA announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the American Thoracic Society International Conference that was held in Washington DC between the 19th and 24th of May 2023.
-
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
5/15/2023
Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.
-
Successful Capital Increase for Biophytis with €2.3 million Raised
5/11/2023
Biophytis SA is announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders' preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual investors via the PrimaryBid platform up to €0.4M on the other hand.
-
Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros
5/10/2023
Biophytis SA announced the launch of a round of fundraising for approximately 2 million euros based on issuing new shares for professional investors, as defined below, and retail investors .
-
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
5/9/2023
Biophytis SA announced that it has filed for a pre-submission meeting request with the European Medicine Agency to discuss filing for conditional Marketing Authorisation in Europe for Sarconeos in the treatment of severe form of COVID-19.
-
Biophytis Strengthens its Management Team
5/2/2023
Biophytis SA announces the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance and the upcoming arrival of Nicolas Fellmann as Chief Financial Officer as of 22 May 2022.
-
Biophytis Announces Receipt of Nasdaq Notice - April 28, 2023
4/28/2023
Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 24, 2023, indicating that, based on the reported stockholders' equity of of Biophytis as reported in its 20-F, the Company does not meet the minimum shareholders' equity criteria of $2,500,000 in stockholders' equity for continued listing.
-
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
4/19/2023
Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 14, 2022, indicating that Biophytis has regained compliance with he Nasdaq Global Select Market minimum bid price requirement.
-
Biophytis Announces 2022 Financial Results and 2023 Perspectives
4/18/2023
Biophytis SA announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023.
-
Biophytis: Results of the Combined General Meeting on April 17, 2023
4/18/2023
Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting.
-
Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023
3/30/2023
Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, informed that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached.
-
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
3/27/2023
Biophytis SA announced that it has held a presentation on their drug candidate, Sarconeos, as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research.
-
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
3/17/2023
Biophytis SA annouces that it will change the ratio of its American Depositary Shares to Biophytis ordinary shares from one ADS representing 10 Shares, to one ADS representing 100 Shares.
-
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
3/9/2023
Biophytis SA announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023.
-
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
3/2/2023
Biophytis SA announced that it has signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.
-
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
2/27/2023
Biophytis SA, announced that it has begun the process of early access application in France from the French National Authority for Health for the treatment of severe COVID-19 with Sarconeos.
-
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
2/23/2023
Biophytis SA announced it is convening an Extraordinary and Ordinary Shareholders' Meeting for March 30, 2023.
-
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
2/2/2023
Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
-
Biophytis Publishes its Financial Results for the First Half of 2022
1/31/2023
Biophytis SA publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021.
-
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice
1/12/2023
Biophytis SA received a deficiency notice from The Nasdaq Stock Market, Inc. stating that the Company has not filed its financial information for the six-month period ended June 30, 2022 on a Form 6-K and as a result the Company no longer complies with Nasdaq's listing rules for continued listing set forth in the Listing Rule 5250.